Spondyloarthritis & psoriatic arthritis
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
Authors' conclusion
Comorbidities may influence both the effectiveness of a given therapy but also the potential for adverse events.
Study context
- Population
- Patients with psoriatic arthritis (PsA) and comorbidities
- Outcome
- Common comorbidities in PsA that may affect treatment selection
Main finding
As reported in the abstract
- Baseline cardiovascular disease (CVD) or high risk for CVD
- Obesity and metabolic syndrome
- Liver disease
- Mood disorders, in particular depression
- Chronic infections
- Malignancies
- Osteoporosis
- FM and/or central sensitization
- Informs the 2021 GRAPPA treatment recommendations
Original publication
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →